CAMPATH: from concept to clinic

Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1707-11. doi: 10.1098/rstb.2005.1702.


Lymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has established it as a licensed drug for the management of chronic lymphocyte leukaemia. Short-term therapy with alemtuzumab has demonstrated long-term benefit in a number of autoimmune conditions. This drug has the potential to facilitate recruitment of tolerance processes so enabling drug minimization in transplantation, autoimmune and hypersensitivity diseases.

Publication types

  • Review

MeSH terms

  • Alemtuzumab
  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / immunology*
  • Antibodies, Neoplasm / therapeutic use*
  • Graft vs Host Disease / drug therapy*
  • Graft vs Host Disease / immunology
  • Humans
  • Immune Tolerance / immunology*
  • Lymphocyte Depletion / methods*
  • Models, Immunological*
  • T-Lymphocytes / immunology*


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Alemtuzumab